🇺🇸 FDA

Intelligence · Clinical Pipeline

Regeneron UK Pipeline

All ClinicalTrials.gov programs at Regeneron UK — phase, modality, and trial IDs.

Programs
493

Quick answer

Regeneron UK has 493 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 2-mg Intravitreous Aflibercept Injection

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  2. 2.0 mg intravitreal aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  3. 8 mg aflibercept (BAY 86-5321) (High Dose)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  4. Aflibercept

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule completed

    3 trials

  5. Aflibercept

    Regeneron UK Limited

    Prostatic Neoplasms

    phase 3 small molecule completed

    1 trial

  6. Aflibercept (EYLEA, BAY86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  7. Aflibercept (Eylea, BAY 86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  8. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    phase 3 mab completed

    1 trial

  9. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  10. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial

  11. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Carcinoma

    phase 3 small molecule completed

    1 trial

  12. Aflibercept 8 mg

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  13. Aflibercept AVE0005

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule terminated

    2 trials

  14. Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  15. Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  16. Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  17. Alirocumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  18. Alirocumab

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  19. Alirocumab

    Regeneron UK Limited

    Coronary Vessel

    phase 3 small molecule completed

    1 trial

  20. Alirocumab

    Regeneron UK Limited

    Type2 Diabetes

    phase 3 small molecule completed

    1 trial

  21. Alirocumab

    Regeneron UK Limited

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  22. Alirocumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule active

    18 trials

  23. Alirocumab 150 MG/ML [Praluent]

    Regeneron UK Limited

    Hemodialysis

    phase 3 small molecule active

    1 trial

  24. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    1 trial

  25. Atorvastatin

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  26. CMP-001

    Regeneron UK Limited

    Melanoma

    phase 3 small molecule completed

    3 trials

  27. Cemdisiran

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  28. Cemiplimab

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 3 small molecule active

    7 trials

  29. Cemiplimab

    Regeneron UK Limited

    Squamous Cell Carcinoma (SCC)

    phase 3 small molecule completed

    1 trial

  30. Cemiplimab

    Regeneron UK Limited

    Recurrent Lung Non-Small Cell Carcinoma

    phase 3 mab active

    1 trial

  31. Cemiplimab

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  32. Dupilumab

    Regeneron UK Limited

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule active

    2 trials

  33. Dupilumab

    Regeneron UK Limited

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  34. Dupilumab

    Regeneron UK Limited

    Lichen Simplex Chronicus

    phase 3 small molecule active

    2 trials

  35. Dupilumab

    Regeneron UK Limited

    Wheezing

    phase 3 small molecule active

    1 trial

  36. Dupilumab Prefilled Syringe

    Regeneron UK Limited

    Asthma Control

    phase 3 small molecule active

    1 trial

  37. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  38. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis Without Nasal Polyps

    phase 3 small molecule completed

    1 trial

  39. Dupilumab SAR231893

    Regeneron UK Limited

    Cold Urticaria

    phase 3 small molecule completed

    1 trial

  40. Dupilumab SAR231893

    Regeneron UK Limited

    Allergic Fungal Rhinosinusitis

    phase 3 small molecule completed

    1 trial

  41. Dupilumab SAR231893

    Regeneron UK Limited

    Neurodermatitis

    phase 3 small molecule completed

    2 trials

  42. Dupilumab SAR231893

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    1 trial

  43. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  44. Dupilumab SAR231893 (REGN668)

    Regeneron UK Limited

    Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

    phase 3 small molecule completed

    2 trials

  45. Dupilumab SAR231893 (REGN668)

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    2 trials

  46. Eylea (Aflibercept, BAY86-5321)

    Regeneron UK Limited

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    2 trials

  47. Fasinumab

    Regeneron UK Limited

    Chronic Low Back Pain

    phase 3 small molecule terminated

    1 trial

  48. Fasinumab

    Regeneron UK Limited

    Low Back Pain

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Regeneron UK have?

493 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.